Background
Despite the development of various antiviral drugs, most of them are not effective in the treatment of coronavirus disease 2019 (COVID-19) as a hyperinflammatory disorder. Chemokine (C-C motif) ligand 2 (CCL2) is one of the critical CC chemokines involved in the pathogenesis and severity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This study aimed to investigate the expression of CCL2 and CC chemokine receptor 2 (CCR2) in COVID-19 patients.
Methods
Peripheral blood samples were collected from 60 confirmed COVID-19 patients and 60 age-matched healthy subjects. The ages of the subjects were categorized as follows: up to 20 years, 20 to 40 years, 40 to 60 years, and more than 60 years. CCL2 serum levels were measured using the enzyme-linked immunosorbent assay (ELISA).
CCR2
gene expression in peripheral blood mononuclear cells (PBMCs) was measured employing real-time polymerase chain reaction (PCR).
Results
In all age groups, CCL2 serum levels were significantly elevated in patients compared to healthy controls (
P
< 0.0001). CCL2 levels were higher in severe patients than in moderate patients. Moreover,
CCR2
expression by PBMCs was higher in patients compared to control subjects. However, a significant difference between patients and controls over 60 years of age was identified (
P
= 0.0353). There was no significant difference in
CCR2
expression between moderate and severe COVID-19 patients.
Conclusions
Taken together, the findings demonstrate that CCL2 and
CCR2
are upregulated in COVID-19 patients at protein and mRNA levels, respectively. Therefore, the CCL2/CCR2 axis may be a potential therapeutic target in order to improve patient outcomes.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12865-024-00662-8.